FDA Accepts Supplemental Application for PERJETA by Genentech
The FDA has accepted a supplemental application for PERJETA (pertuzumab) from Genentech.
Asset / Drug
Drug and asset intelligence for PERJETA with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
HER2 Inhibitor
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.